Cracking the Code: Read Analyst Comments on AtriCure – AtriCure (NASDAQ:ATRC)
During the most recent quarter, 6 analysts provided ratings for AtriCure ATRCshowing a mix of bullish and bearish views.
The table below summarizes their most recent ratings, giving us a glimpse of changing sentiment over the last 30 days and comparing it to previous months.
| bullish | somewhat bullish | indifferent | A bit bearish | Bearish | |
|---|---|---|---|---|---|
| Overall rating | 4 | 2 | 0 | 0 | 0 |
| last 30 days | 1 | 0 | 0 | 0 | 0 |
| 1 million years ago | 0 | 0 | 0 | 0 | 0 |
| 2M ago | 3 | 2 | 0 | 0 | 0 |
| 3M ago | 0 | 0 | 0 | 0 | 0 |
Analyst insights on 12-month price targets are revealed, with the average target at $45.0, with the highest estimate at $61.00 and the lowest estimate at $36.00. This upward trend is evident, with the current average price representing a 15.89% upside from the previous average price target of $38.83.
Surveying Analyst Ratings: An Exhaustive Study
AtriCure’s standing among financial experts becomes clear through a thorough analysis of recent analyst action. The summary below provides an overview of the leading analysts, their most recent assessments, and changes to ratings and price targets.
| analyst | Analyst Company | action taken | grade | Current price target | Previous price target |
|---|---|---|---|---|---|
| William Plovnik | Canaccord Genius | improve | purchase | $61.00 | $53.00 |
| William Plovnik | Canaccord Genius | improve | purchase | $53.00 | $49.00 |
| Suraj Kaliya | Oppenheimer | improve | Outperform | $36.00 | $32.00 |
| Robbie Marcus | JPMorgan Chase | improve | overweight | $40.00 | $30.00 |
| Danielle Antafi | UBS | improve | purchase | $40.00 | $35.00 |
| Mike Mattson | Joseph Needham | improve | purchase | $40.00 | $34.00 |
Key insights:
- Action taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they “maintain,” “raise,” or “lower” their stance reflects their reaction to the latest developments related to AtriCure. This information provides a snapshot of how analysts view a company’s current situation.
- grade: Analysts provide qualitative assessments of the stock, ranging from “outperform” to “underperform.” These ratings convey analysts’ expectations for AtriCure’s relative performance compared to the broader market.
- Price target: Analysts explore price target dynamics, providing estimates of AtriCure stock’s future value. This examination reveals how analyst expectations have changed over time.
Considering these analyst assessments in conjunction with other financial metrics provides a complete picture of AtriCure’s market position. Stay informed and make informed decisions with our ratings tables.
Stay up to date with AtriCure analyst ratings.
If you’re interested in following small-cap news and performance, you can start tracking here.
Discovering AtriCure: A closer look
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and postoperative pain management, and markets its products to medical centers through its direct sales force and distributors. Its product lines include cryotherapy, soft tissue dissection, radiofrequency ablation pacing and sensing. The company also offers a variety of minimally invasive ablation devices and access tools to contribute to the growing trend of minimally invasive cardiac and thoracic surgeries. Geographically, it generates most of its revenue from the United States.
Financial Insights: AtriCure
Market value analysis: The company’s market capitalization is lower than the industry average, indicating a relatively small size compared to its peers. This may be due to a number of factors, including perceived growth potential or scale of operations.
Revenue growth: AtriCure shows positive results within 3 months. As of September 30, 2024, the company has achieved approximately 17.93%. This shows significant revenue growth for the company. Compared with its peers, the company’s growth rate is higher than the average of its peers in the medical and health industry.
net income: AtriCure’s net margin is below the industry average, indicating the challenges of achieving strong profitability. Net profit is -6.78%, Companies may face barriers to effective cost management.
Return on Equity (ROE): The company’s ROE performs well and beats the industry average. Has an impressive ROE -1.69%, The company’s equity capital is used effectively.
Return on assets (ROA): AtriCure’s ROA lags the industry average, indicating challenges in maximizing returns on its assets. ROA is -1.3%, Companies may face obstacles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach, with a debt-to-equity ratio below industry norms and at 0.17.
Understand the correlation of analyst ratings
Analysts work in the banking and financial systems, often focusing on reporting on stocks or specific industries. Analysts can participate in company calls and meetings, study company financial statements, and communicate with insiders to issue “analyst ratings” for stocks. Analysts typically rate each stock quarterly.
Analysts may supplement their ratings with forecasts on metrics such as growth expectations, earnings and revenue to provide investors with a more comprehensive outlook. However, investors should be aware that analysts, like anyone, may have subjective views that influence their forecasts.
BREAKING: Wall Street’s next big mover
Benzinga’s top analysts just discovered a stock that’s poised for explosive growth. This under-the-radar company could surge more than 200% as a major market shift unfolds. Click here for emergency details.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
Market news and data brought to you by Benzinga API
© 2024 Benzinga.com. Benzinga does not provide investment advice. all rights reserved.
